| 1 | CERS6, FAS
|
| Ceramide synthase-6 confers resistance to chemotherapy by binding to CD95/Fas in T-cell acute lymphoblastic leukemia
|
| Verlekar D, Wei SJ, Cho H, Yang S, Kang MH.
|
| Cell Death Dis. Sep 11;9(9):925. doi: 10.1038/s41419-018-0964-4. 2018
|
| 2 | BID, FAS, MOAP1, MTCH2
|
| MOAP-1 Mediates Fas-Induced Apoptosis in Liver by Facilitating tBid Recruitment to Mitochondria.
|
| Tan CT, Zhou QL, Su YC, Fu NY, Chang HC, Tao RN, Sukumaran SK, Baksh S, Tan YJ, Sabapathy K, Yu CD, Yu VC.
|
| Cell Rep 16(1):174-185. doi: 10.1016/j.celrep.2016.05.068. Epub 2016 Jun 16.
2016
|
| 3 | FAS, ZDHHC7
|
| Fas palmitoylation by the palmitoyl acyltransferase DHHC7 regulates Fas stability.
|
| Rossin A, Durivault J, Chakhtoura-Feghali T, Lounnas N, Gagnoux-Palacios L, Hueber AO.
|
| Cell Death Differ. Apr;22(4):643-53. doi: 10.1038/cdd.2014.153. Epub 2014 Oct 10. 2015
|
| 4 | FAS, LAT
|
| The membrane adaptor LAT is proteolytically cleaved following Fas engagement in a tyrosine phosphorylation-dependent fashion.
|
| García-Blesa A, Klossowicz M, López-Osuna C, Martínez-Florensa M, Malissen B, García-Cózar FJ, Miazek A, Aguado E.
|
| Biochem J 450(3):511-21. doi: 10.1042/BJ20121135.
2013
|
| 5 | CALM1, FAS
|
| Structural and biophysical characterization of the interactions between the death domain of Fas receptor and calmodulin
|
| Fernandez TF, Samal AB, Bedwell GJ, Chen Y, Saad JS.
|
| J Biol Chem. Jul 26;288(30):21898-908. doi: 10.1074/jbc.M113.471821. Epub 2013 Jun 11. 2013
|
| 6 | FAS, NFKB1, VEGFC
|
| Correlated expression of Fas, NF-kappaB, and VEGF-C in infiltrating ductal carcinoma of the breast.
|
| Dai XL, Zhou SL, Qiu J, Liu YF, Hua H.
|
| Eur J Gynaecol Oncol 33(6):633-9.
2012
|
| 7 | FAS
|
| CD95 signaling in colorectal cancer.
|
| Hoogwater FJ, Steller EJ, Westendorp BF, Borel Rinkes IH, Kranenburg O.
|
| Biochim Biophys Acta 1826(1):189-98. doi: 10.1016/j.bbcan.2012.03.007. Epub 2012 Mar 31.
2012
|
| 8 | FAS, MAP1LC3B
|
| Hyperoxia-induced LC3B interacts with the Fas apoptotic pathway in epithelial cell death.
|
| Tanaka A, Jin Y, Lee SJ, Zhang M, Kim HP, Stolz DB, Ryter SW, Choi AM.
|
| Am J Respir Cell Mol Biol 46(4):507-14. doi: 10.1165/rcmb.2009-0415OC. Epub 2011 Nov 17.
2012
|
| 9 | CFL1, FAS
|
| The death receptor CD95 activates the cofilin pathway to stimulate tumour cell invasion.
|
| Steller EJ, Ritsma L, Raats DA, Hoogwater FJ, Emmink BL, Govaert KM, Laoukili J, Rinkes IH, van Rheenen J, Kranenburg O.
|
| EMBO Rep 12(9):931-7. doi: 10.1038/embor.2011.129. 2011
|
| 10 | CASP8, FADD, FAS, ORAI1
|
| CD95 triggers Orai1-mediated localized Ca2+ entry, regulates recruitment of protein kinase C (PKC) β2, and prevents death-inducing signaling complex formation.
|
| Khadra N, Bresson-Bepoldin L, Penna A, Chaigne-Delalande B, Ségui B, Levade T, Vacher AM, Reiffers J, Ducret T, Moreau JF, Cahalan MD, Vacher P, Legembre P.
|
| Proc Natl Acad Sci U S A 108(47):19072-7. doi: 10.1073/pnas.1116946108. Epub 2011 Nov 7.
2011
|
| 11 | FAS
|
| How CD95 stimulates invasion.
|
| Steller EJ, Borel Rinkes IH, Kranenburg O.
|
| Cell Cycle 10(22):3857-62. doi: 10.4161/cc.10.22.18290. Epub 2011 Nov 15. Review.
2011
|
| 12 | FAS
|
| Does calcium contribute to the CD95 signaling pathway?
|
| Vacher P, Khadra N, Vacher AM, Charles E, Bresson-Bepoldin L, Legembre P.
|
| Anticancer Drugs 22(6):481-7. doi: 10.1097/CAD.0b013e32834433ea. Review.
2011
|
| 13 | FAS
|
| A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation.
|
| Neven B, Magerus-Chatinet A, Florkin B, Gobert D, Lambotte O, De Somer L, Lanzarotti N, Stolzenberg MC, Bader-Meunier B, Aladjidi N, Chantrain C, Bertrand Y, Jeziorski E, Leverger G, Michel G, Suarez F, Oksenhendler E, Hermine O, Blanche S, Picard C, Fischer A, Rieux-Laucat F.
|
| Blood 118(18):4798-807. doi: 10.1182/blood-2011-04-347641. Epub 2011 Sep 1.
2011
|
| 14 | FAS, FASLG
|
| CD95 promotes tumour growth.
|
| Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, Turner JR, Fu YX, Romero IL, Lengyel E, Peter ME.
|
| Nature 465(7297):492-6.PMID: 20505730 2010
|
| 15 | FAS, FASLG
|
| A non-apoptotic role for Fas/FasL in erythropoiesis.
|
| Carlile GW, Smith DH, Wiedmann M.
|
| FEBS Lett 583(4):848-54. 2009
|
| 16 | FAS
|
| Fas promoter region gene polymorphism is associated with an increased risk for myocardial infarction.
|
| Hanasaki H, Takemura Y, Fukuo K, Ohishi M, Onishi M, Yasuda O, Katsuya T, Awata N, Kato N, Ogihara T, Rakugi H.
|
| Hypertens Res 32(4):261-4. Epub 2009 Feb 27.
2009
|
| 17 | FAS, TP53, TP63, TP73
|
| Active transcription of the human FAS/CD95/TNFRSF6 gene involves the p53 family.
|
| Schilling T, Schleithoff ES, Kairat A, Melino G, Stremmel W, Oren M, Krammer PH, Müller M.
|
| Biochem Biophys Res Commun 387(2):399-404. Epub 2009 Jul 16.
2009
|
| 18 | FAS
|
| CD95 engagement mediates actin-independent and -dependent apoptotic signals.
|
| Chaigne-Delalande B, Mahfouf W, Daburon S, Moreau JF, Legembre P.
|
| Cell Death Differ 16(12):1654-64. doi: 10.1038/cdd.2009.111. Epub 2009 Aug 14.
2009
|
| 19 | FAS, FASL, FASLG
|
| CD95 stimulation results in the formation of a novel death effector domain protein-containing complex.
|
| Lavrik IN, Mock T, Golks A, Hoffmann JC, Baumann S, Krammer PH.
|
| J Biol Chem 283(39):26401-8. Epub 2008 Jul 17. 2008
|
| 20 | FAS, YES1
|
| Yes and PI3K bind CD95 to signal invasion of glioblastoma.
|
| Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O, Thiemann M, Mueller W, Sykora J, Kuhn A, Schreglmann N, Letellier E, Zuliani C, Klussmann S, Teodorczyk M, Gröne HJ, Ganten TM, Sültmann H, Tüttenberg J, von Deimling A, Regnier-Vigouroux A, Herold-Mende C, Martin-Villalba A.
|
| Cancer Cell 13(3):235-48.PMID: 18328427 2008
|
| 21 | FAS
|
| Endosomal compartment contributes to the propagation of CD95/Fas-mediated signals in type II cells.
|
| Matarrese P, Manganelli V, Garofalo T, Tinari A, Gambardella L, Ndebele K, Khosravi-Far R, Sorice M, Esposti MD, Malorni W.
|
| Biochem J 413(3):467-78.
2008
|
| 22 | FAS
|
| Mutations within the 5' region of FAS/CD95 gene in nodal diffuse large B-cell lymphoma.
|
| Scholl V, Stefanoff CG, Hassan R, Spector N, Renault IZ.
|
| Leuk Lymphoma 48(5):957-63.
2007
|
| 23 | CASP8AP2, FAS
|
| FLASH links the CD95 signaling pathway to the cell nucleus and nuclear bodies.
|
| Milovic-Holm K, Krieghoff E, Jensen K, Will H, Hofmann TG.
|
| EMBO J 26(2):391-401.
2007
|
| 24 | FAS,YY1
|
| Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosation.
|
| Hongo F, Garban H, Huerta-Yepez S, Vega M, Jazirehi AR, Mizutani Y, Miki T, Bonavida B.
|
| Biochem Biophys Res Commun 336(2):692-701. 2005
|
| 25 | FAS
|
| Further evidence for role of a promoter variant in the TNFRSF6 gene in Alzheimer disease.
|
| Feuk L, Prince JA, Blennow K, Brookes AJ.
|
| Hum Mutat 21(1):53-60. 2003
|
| 26 | FAS
|
| Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia.
|
| Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, Skibola CF, Smith MT, Morgan GJ.
|
| Cancer Res 63(15):4327-30. 2003
|
| 27 | FAS
|
| Frequent mutations of Fas gene in nasal NK/T cell lymphoma.
|
| Takakuwa T, Dong Z, Nakatsuka S, Kojya S, Harabuchi Y, Yang WI, Nagata S, Aozasa K.
|
| Oncogene 21(30):4702-5. 2002
|
| 28 | FAS
|
| A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma.
|
| van Doorn R, Dijkman R, Vermeer MH, Starink TM, Willemze R, Tensen CP.
|
| Cancer Res 62(19):5389-92. 2002
|
| 29 | FAS
|
| The TNFRSF6 gene is not implicated in familial early-onset Alzheimer's disease.
|
| Theuns J, Feuk L, Dermaut B, Del-Favero J, Roks G, Van den Bossche D, Corsmit E, Van den Broeck M, van Duijn CM, Cruts M, Brookes AJ, Van Broeckhoven C.
|
| Hum Genet 108(6):552-3. No abstract available. 2001
|
| 30 | FAS
|
| Frequent mutations of Fas gene in thyroid lymphoma.
|
| Takakuwa T, Dong Z, Takayama H, Matsuzuka F, Nagata S, Aozasa K.
|
| Cancer Res 61(4):1382-5. 2001
|
| 31 | FAS
|
| Promoter region methylation does not account for the frequent loss of expression of the Fas gene in colorectal carcinoma.
|
| Butler LM, Dobrovic A, Bianco T, Cowled PA.
|
| Br J Cancer 82(1):131-5. 2000
|
| 32 | FAS, FASLG
|
| Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations.
|
| Siegel RM, Frederiksen JK, Zacharias DA, Chan FK, Johnson M, Lynch D, Tsien RY, Lenardo MJ.
|
| Science 288(5475):2354-7. 2000
|
| 33 | FAS
|
| CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway.
|
| Parlato S, Giammarioli AM, Logozzi M, Lozupone F, Matarrese P, Luciani F, Falchi M, Malorni W, Fais S.
|
| EMBO J 19(19):5123-5134. 2000
|
| 34 | CSS1, FAS
|
| The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations.
|
| Vaishnaw AK, et al.
|
| J Clin Invest 103(3):355-63. 1999
|
| 35 | CSS1, FAS
|
| Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia.
|
| Martin DA, et al.
|
| Proc Natl Acad Sci U S A 96(8):4552-7. 1999
|
| 36 | FAS
|
| Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease.
|
| Peters AM, et al.
|
| Exp Hematol 27(5):868-74. 1999
|
| 37 | FASLG, FAS
|
| FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier.
|
| Bechmann I, et al.
|
| Glia 27(1):62-74 1999
|
| 38 | FAS
|
| Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer.
|
| Lee SH, et al.
|
| Oncogene 18(25):3754-60 1999
|
| 39 | FAS
|
| Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis.
|
| De Maria R, et al.
|
| Blood 93(3):796-803 1999
|
| 40 | FAS
|
| Involvement of soluble CD95 in Churg-Strauss syndrome.
|
| Muschen M, Warskulat U, Perniok A, Even J, Moers C, Kismet B, Temizkan N, Simon D, Schneider M, Haussinger D.
|
| Am J Pathol 155(3):915-25 1999
|
| 41 | FAS
|
| Stimulation of CD95 (Fas) blocks T lymphocyte calcium channels through sphingomyelinase and sphingolipids.
|
| Lepple-Wienhues A, Belka C, Laun T, Jekle A, Walter B, Wieland U, Welz M, Heil L, Kun J, Busch G, Weller M, Bamberg M, Gulbins E, Lang F.
|
| Proc Natl Acad Sci U S A 96(24):13795-800 1999
|
| 42 | FAS
|
| Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor.
|
| Papoff G, Hausler P, Eramo A, Pagano MG, Di Leve G, Signore A, Ruberti G.
|
| J Biol Chem 274(53):38241-50. 1999
|
| 43 | FAS
|
| The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO-1) mutations.
|
| Vaishnaw AK, Toubi E, Ohsako S, Drappa J, Buys S, Estrada J, Sitarz A, Zemel L, Chu JL, Elkon KB.
|
| Arthritis Rheum 42(9):1833-42. 1999
|
| 44 | PHLDA1, FASLG, FAS
|
| A proline- and glutamine-rich protein promotes apoptosis in neuronal cells.
|
| Gomes I, Xiong W, Miki T, Rosner MR.
|
| J Neurochem 73(2):612-22. 1999
|
| 45 | BRCA1, FAS, RAD50
|
| Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response.
|
| Zhong Q, Chen CF, Li S, Chen Y, Wang CC, Xiao J, Chen PL, Sharp ZD, Lee WH.
|
| Science. 285(5428):747-50. 1999
|
| 46 | FAS, TAL4
|
| CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia.
|
| Beltinger C, et al.
|
| Blood 91 : 3943-3951. 1998
|
| 47 | FAS, TAL4
|
| Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells.
|
| Tamiya S, et al.
|
| Blood 91 : 3935-3942. 1998
|
| 48 | CSS1, FAS
|
| Novel Fas (CD95/APO-1) mutations in infants with a lymphoproliferative disorder.
|
| Kasahara Y, et al.
|
| Int Immunol 10(2):195-202. 1998
|
| 49 | CSS1, FAS
|
| Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome : a molecular and immunological analysis.
|
| Bettinardi A, et al.
|
| Blood 89 : 902-909. 1997
|
| 50 | FAS
|
| The role of Fas in autoimmune diabetes.
|
| Chervonsky AV, Wang Y, Wong FS, Visintin I, Flavell RA, Janeway CA Jr, Matis LA.
|
| Cell 89 : 17-24. 1997
|
| 51 | CSS1, FAS
|
| Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
|
| Sneller MC, et al.
|
| Blood 89(4):1341-8. 1997
|
| 52 | CSS2, CSS1, FAS
|
| Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity.
|
| Drappa J, et al.
|
| N Engl J Med 335(22):1643-9. 1996
|
| 53 | PHLDA1, FASLG, FAS
|
| A novel gene product that couples TCR signaling to Fas(CD95) expression in activation-induced cell death.
|
| Park CG, Lee SY, Kandala G, Lee SY, Choi Y.
|
| Immunity 4(6):583-91. 1996
|
| 54 | CASP3, CASP4, CASP5, FAS
|
| Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis.
|
| Enari M, Talanian RV, Wong WW, Nagata S.
|
| Nature 380(6576):723-6. 1996
|
| 55 | FAS
|
| CD95 (FAS/APO-1) antibody-mediated apoptosis of human retinal pigment epithelial cells.
|
| Esser P, et al.
|
| Biochem Biophys Res Commun 213 : 1026-1034. 1995
|
| 56 | FAS, FAS
|
| The Fas death factor.
|
| Nagata S, et al.
|
| Science 267 : 1449-1455. 1995
|
| 57 | FAS, CSS1
|
| Mutations in fas associated with human lymphoproliferative syndrome and autoimmunity.
|
| Rieux-Laucat F, et al.
|
| Science 268 : 1347-1349. 1995
|
| 58 | CSS1, FAS
|
| Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome.
|
| Fisher GH, et al.
|
| Cell 81 : 935-946. 1995
|
| 59 | FAS
|
| Detection of polymorphisms within the FAS cDNA gene sequence by GC-clamp denaturing gradient gel electrophoresis.
|
| Fiucci G, et al.
|
| Immunogenetics 39 : 437-439. 1994
|
| 60 | FAS
|
| The human APO-1 (APT) antigen maps to 10q23, a region that is syntenic with mouse chromosome 19.
|
| Lichter P, et al.
|
| Genomics 14 : 179-180. 1992
|
| 61 | FAS
|
| Assignment of the human fas antigen gene (FAS) to 10q24.1.
|
| Inazawa J, et al.
|
| Genomics 14 : 821-822. 1992
|
| 62 | FAS
|
| Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen.
|
| Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li-Weber M, Richards S, Dhein J, Trauth BC, et al.
|
| J Biol Chem 267(15):10709-15.
1992
|